Comparative Effectiveness of Mannitol Versus Hypertonic Saline in Patients With Traumatic Brain Injury: A CENTER-TBI Study

医学 甘露醇 高渗盐水 创伤性脑损伤 创伤中心 队列研究 颅内压 麻醉 内科学 急诊医学 儿科 回顾性队列研究 精神科 化学 有机化学
作者
Ernest van Veen,Daan Nieboer,Erwin J. O. Kompanje,Giuseppe Citerio,Nino Stocchetti,Diederik Gommers,David Menon,Ari Ercole,Andrew I.R. Maas,Hester F. Lingsma,Mathieu van der Jagt
出处
期刊:Journal of Neurotrauma [Mary Ann Liebert, Inc.]
卷期号:40 (13-14): 1352-1365 被引量:20
标识
DOI:10.1089/neu.2022.0465
摘要

Increased intracranial pressure (ICP) is one of the most important modifiable and immediate threats to critically ill patients suffering from traumatic brain injury (TBI). Two hyperosmolar agents (HOAs), mannitol and hypertonic saline (HTS), are routinely used in clinical practice to treat increased ICP. We aimed to assess whether a preference for mannitol, HTS, or their combined use translated into differences in outcome. The Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) Study is a prospective multi-center cohort study. For this study, patients with TBI, admitted to the intensive care unit (ICU), treated with mannitol and/or HTS, and aged ≥16 years were included. Patients and centers were differentiated based on treatment preference with mannitol and/or HTS based on structured, data-driven criteria such as first administered HOA in the ICU. We assessed influence of center and patient characteristics in the choice of agent using adjusted multi-variate models. Further, we assessed the influence of HOA preference on outcome using adjusted ordinal and logistic regression models, and instrumental variable analyses. In total, 2056 patients were assessed. Of these, 502 (24%) patients received mannitol and/or HTS in the ICU. The first received HOA was HTS for 287 (57%) patients, mannitol for 149 (30%) patients, or both mannitol and HTS on the same day for 66 (13%) patients. Two unreactive pupils were more common in patients receiving both (13, 21%), compared with patients receiving HTS (40, 14%) or mannitol (22, 16%). Center, rather than patient characteristics, was independently associated with the preferred choice of HOA ( p -value <0.05). ICU mortality and 6-month outcome were similar between patients preferably treated with mannitol compared with HTS (odds ratio [OR] = 1.0, confidence interval [CI] = 0.4–2.2; OR = 0.9, CI = 0.5–1.6, respectively). Patients who received both also had a similar ICU mortality and 6-month outcome compared with patients receiving HTS (OR = 1.8, CI = 0.7–5.0; OR = 0.6, CI = 0.3–1.7, respectively). We found between-center variability regarding HOA preference. Moreover, we found that center is a more important driver of the choice of HOA than patient characteristics. However, our study indicates that this variability is an acceptable practice given absence of differences in outcomes associated with a specific HOA.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
liuyaru完成签到,获得积分20
2秒前
3秒前
彭于晏的应助被风吹麦浪采纳,获得10
3秒前
香蕉觅云的应助被artyremix采纳,获得10
3秒前
帅气的沛蓝关注了科研通微信公众号
3秒前
3秒前
缓慢的水之完成签到,获得积分10
3秒前
喜羊羊完成签到,获得积分10
4秒前
4秒前
4秒前
在水一方的应助被Needle采纳,获得10
5秒前
6秒前
权瑞松完成签到,获得积分10
6秒前
MIMOSA完成签到 ,获得积分10
6秒前
6秒前
7秒前
77完成签到,获得积分10
7秒前
liuyaru发布了新的文献求助30
7秒前
我是老大的应助被恒裕常采纳,获得10
8秒前
大吱吱发布了新的文献求助10
8秒前
Hello的应助被jxq采纳,获得10
9秒前
科研通AI65的应助被沉淀采纳,获得10
9秒前
10秒前
10秒前
彭于晏的应助被cjh采纳,获得10
10秒前
山川行里发布了新的文献求助10
10秒前
11秒前
11秒前
xujie发布了新的文献求助10
11秒前
genandtal发布了新的文献求助10
11秒前
make完成签到,获得积分10
11秒前
12秒前
12秒前
飞翔的应助被嘻嘻哈哈采纳,获得90
12秒前
12完成签到 ,获得积分10
13秒前
Lev发布了新的文献求助10
13秒前
14秒前
14秒前
15秒前
念汐发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191695
求助须知:如何正确求助?哪些是违规求助? 9578408
关于积分的说明 21859277
捐赠科研通 7791024
什么是DOI,文献DOI怎么找? 3436695
关于科研通互助平台的介绍 2560412
邀请新用户注册赠送积分活动 2483485